Sunday, June 21, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 160 of 1,261

  1. US 11806337

    Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted

  2. US 11806400

    Injectable ibuprofen formulation

    Cumberland Pharmaceuticals Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted

  3. US 11806367

    Methods of treating lysosomal disorders

    The Regents of the University of California · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted

  4. US 11807853

    Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and cancer

    The Board of Regents of the University of Texas System · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted

  5. US 11806504

    Device, system and methods for the oral delivery of therapeutic compounds

    Rani Therapeutics, LLC · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted

  6. US 11807682

    M971 chimeric antigen receptors

    The United States of America, as represented by the Secretary, Department of Heath and Human Services · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted

  7. US 11806408

    Methods and compositions for treating cone-rod retinal dystrophy

    Editas Medicine, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted

  8. US 11807605

    Human plasma kallikrein inhibitors

    BioCryst Pharmaceuticals, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted

  9. US 11807674

    Hepcidin analogues and uses thereof

    Protagonist Therapeutics, Inc. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted

  10. US 11806421

    Porous-cellulose particles and production method thereof, and cosmetic

    JGC Catalysts and Chemicals Ltd. · Granted Nov 7, 2023 · Expires Nov 2, 2043

    granted

  11. US 11802110

    2-amino-N-(arylsulfinyl)-acetamide compounds as inhibitors of bacterial aminoacyl-tRNA synthetase

    Oxford Drug Design Limited · Granted Oct 31, 2023 · Expires Oct 26, 2043

    granted

  12. US 11801265

    Preparation method of NK cells and use thereof in the treatment of cancer

    SINO UNITED (BEIJING) BIOMEDICAL TECHNOLOGY CO., LTD. · Granted Oct 31, 2023 · Expires Oct 26, 2043

    granted

  13. US 11802131

    Glutarimides for medical treatment

    C4 THERAPEUTICS, INC. · Granted Oct 31, 2023 · Expires Oct 26, 2043

    granted

  14. US 11801257

    Stimulation of an immune response by enantiomers of cationic lipids

    PDS Biotechnology Corporation · Granted Oct 31, 2023 · Expires Oct 26, 2043

    granted

  15. US 11802157

    Methods and compositions for modulating CAR-T activity

    Sana Biotechnology, Inc. · Granted Oct 31, 2023 · Expires Oct 26, 2043

    granted

  16. US 11802283

    Oligonucleotide analogues targeting human LMNA

    The United States of America as Represented by the Secretary, Dept. of Health and Human Services · Granted Oct 31, 2023 · Expires Oct 26, 2043

    granted

  17. US 11801241

    Muscarinic M2 receptor blockade to delay or prevent onset of progressive memory decline

    United States Government as represented by the Department of Veterans Affairs · Granted Oct 31, 2023 · Expires Oct 26, 2043

    granted

  18. US 11801268

    Methods of treating ocular inflammation and chemical injuries of the eye with extracellular vesicles

    Capricor, Inc. · Granted Oct 31, 2023 · Expires Oct 26, 2043

    granted

  19. US 11801250

    Pharmaceutical compositions comprising meloxicam

    AXSOME THERAPEUTICS, INC. · Granted Oct 31, 2023 · Expires Oct 26, 2043

    granted

  20. US 11801288

    Cancer vaccines and methods of treatment using the same

    Inovio Pharmaceuticals, Inc. · Granted Oct 31, 2023 · Expires Oct 26, 2043

    granted

  21. US 11801269

    Compositions and methods for transplantation of colon microbiota

    Regents of the University of Minnesota · Granted Oct 31, 2023 · Expires Oct 26, 2043

    granted

  22. US 11801218

    Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine

    The Board of Regents of the University of Texas System · Granted Oct 31, 2023 · Expires Oct 26, 2043

    granted

  23. US 11801295

    Immunogenic compositions and uses thereof

    The Board of Regents of the University of Texas System · Granted Oct 31, 2023 · Expires Oct 26, 2043

    granted

  24. US 11801298

    MERS-CoV vaccine

    Inovio Pharmaceuticals, Inc. · Granted Oct 31, 2023 · Expires Oct 26, 2043

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.